Toll Free: 1-888-928-9744

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Nervous System) pipeline landscape.

Infantile spasms are a type of epilepsy with a characteristic age of onset (typical age when seizures start), pattern of seizures and electroencephalogram (EEG). Symptoms include typical pattern is of a sudden flexion (bending forward) in a tonic (stiffening) fashion of the body, arms and legs. Sometimes, the episodes are different, with the arms and legs being flung outwards (these are called 'extensor' spasms). Causes include central nervous system infections, abnormal brain development or injury, genetic abnormalities (Down syndrome, Miller-Dieker syndrome) and metabolic disorders (mitochondrial diseases, phenylketonuria, and hypoglycemia). Treatment includes antiepileptic medications. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.Infantile Spasm (West Syndrome).

Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Infantile Spasm (West Syndrome) Overview 6 Therapeutics Development 7 Pipeline Products for Infantile Spasm (West Syndrome) - Overview 7 Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies 8 Infantile Spasm (West Syndrome) - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Infantile Spasm (West Syndrome) - Products under Development by Companies 11 Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development 12 Anavex Life Sciences Corp 12 Catalyst Pharmaceuticals Inc 13 GW Pharmaceuticals Plc 14 INSYS Therapeutics Inc 15 Novartis AG 16 Retrophin Inc 17 Infantile Spasm (West Syndrome) - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ANAVEX-273 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 AVL-5189 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 cannabidiol - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 cannabidiol - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 cosyntropin - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 cosyntropin ER - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 CPP-115 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 JBPOS-0101 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Infantile Spasm (West Syndrome) - Dormant Projects 52 Infantile Spasm (West Syndrome) - Product Development Milestones 53 Featured News & Press Releases 53 Sep 19, 2016: Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports 53 Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms 53 Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) 54 May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms 54 Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD 55 Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 55 Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms 56 Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 56 Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115 57 Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia 58 Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome 58 Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference 59 Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry 60 Dec 13, 2011: Catalyst Starts Phase Ia Safety Study For CPP-115 60 Dec 02, 2011: Catalyst To Present Data On CPP-115 At American Epilepsy Society's 65th Annual Meeting 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Infantile Spasm (West Syndrome) - Pipeline by Anavex Life Sciences Corp, H2 2016 12 Infantile Spasm (West Syndrome) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016 13 Infantile Spasm (West Syndrome) - Pipeline by GW Pharmaceuticals Plc, H2 2016 14 Infantile Spasm (West Syndrome) - Pipeline by INSYS Therapeutics Inc, H2 2016 15 Infantile Spasm (West Syndrome) - Pipeline by Novartis AG, H2 2016 16 Infantile Spasm (West Syndrome) - Pipeline by Retrophin Inc, H2 2016 17 Assessment by Monotherapy Products, H2 2016 18 Number of Products by Stage and Target, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Infantile Spasm (West Syndrome) - Dormant Projects, H2 2016 52



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify